Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Atezolizumab
Related studies linked through entity extraction aliases.
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Status
- RECRUITING
- Phase
- PHASE1